Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492009 | 0.87 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL4479812 | 0.82 | CRHR1 (0.39) | CRHR1MAPTALDH1A1KDM4E | |
| SCHEMBL4498283 | 0.78 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL4494321 | 0.78 | CRHR1 (0.44) | CRHR1MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL4480818 | 0.78 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL4500640 | 0.76 | CRHR1 (0.47) | CRHR1MAPTALDH1A1GAAKDM4E | |
| SCHEMBL4487108 | 0.75 | CRHR1 (0.34) | CRHR1 | |
| SCHEMBL4483814 | 0.74 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL4499176 | 0.65 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL4486617 | 0.64 | CDC7 (0.47) | CRHR1ALDH1A1KDM4EHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281120-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1961745-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281120-A1 | BICYCLIC HETEROCYCLIC COMPOUND | CRHR1, NR3C1, CNR1 | CRHR1 1/4885MAPT 3884/4885ALDH1A1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.